Edition:
India

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

10.84USD
24 Feb 2020
Change (% chg)

-- (--)
Prev Close
$10.84
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
63,556
52-wk High
$17.80
52-wk Low
$5.36

Latest Key Developments (Source: Significant Developments)

Concert Pharmaceuticals Announces Pricing Of Public Offering
Tuesday, 28 Jan 2020 

Jan 28 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING.CONCERT PHARMACEUTICALS INC - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 4.7 MILLION SHARES OF COMMON STOCK AT PUBLIC OFFERING PRICE OF $9.92PER SHARE.  Full Article

Concert Announces Notice Of Allowance For Patent Application Of CTP-543
Wednesday, 22 Jan 2020 

Jan 22 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS ANNOUNCES NOTICE OF ALLOWANCE FOR U.S. PATENT APPLICATION RELATED TO CTP-543, LEAD CANDIDATE FOR TREATMENT OF ALOPECIA AREATA.CONCERT PHARMACEUTICALS INC - CLAIMS COVER PHARMACEUTICAL COMPOSITIONS OF CTP-543 AND METHODS OF TREATING ALOPECIA AREATA WITH CTP-543.CONCERT PHARMACEUTICALS INC - NEW PATENT EXPECTED TO EXPIRE IN 2037.CONCERT PHARMACEUTICALS - EXPECTS TO ADVANCE CTP-543 INTO PHASE 3 EVALUATION FOR ALOPECIA AREATA IN 2020.  Full Article

Concert Pharma Reports Positive Results From Early-Stage Studies Testing Its Experimental Schizophrenia Treatment
Wednesday, 12 Jun 2019 

June 12 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS POSITIVE RESULTS FROM PHASE 1 STUDIES EVALUATING CTP-692 IN HEALTHY VOLUNTEERS.CONCERT PHARMACEUTICALS INC - EXPECTS TO INITIATE A PHASE 2 TRIAL IN PATIENTS WITH SCHIZOPHRENIA IN Q4 OF 2019.CONCERT PHARMA - SAFETY ASSESSMENTS IN SINGLE- & MULTIPLE-ASCENDING DOSE TRIALS IN HEALTHY VOLUNTEERS SHOWED DRUG WAS WELL TOLERATED OVER DOSE RANGES TESTED.CONCERT PHARMACEUTICALS - STUDY SHOWED KEY BLOOD AND URINE MARKERS OF KIDNEY FUNCTION DID NOT INDICATE ANY SIGNS OF RENAL IMPAIRMENT.  Full Article

Concert Pharmaceuticals Says Intend To Appeal Decision From Patent Trial
Tuesday, 9 Apr 2019 

April 8 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS ANNOUNCES DECISION FROM PATENT TRIAL AND APPEAL BOARD IN IPR PROCEEDING.CONCERT PHARMACEUTICALS INC - DISAPPOINTED IN OUTCOME FROM PATENT TRIAL AND APPEAL BOARD IN IPR PROCEEDING.CONCERT PHARMACEUTICALS INC - INTEND TO APPEAL DECISION AS WE WORK TO CREATE ADDITIONAL INTELLECTUAL PROPERTY PROTECTING CTP-543.CONCERT PHARMACEUTICALS INC - DEVELOPMENT TIMELINES FOR CTP-543 REMAIN ON TRACK..CONCERT PHARMACEUTICALS INC - DECISION IS SPECIFIC TO CERTAIN PATENT CLAIMS COVERING CTP-543 AND DOES NOT AFFECT OTHER PROGRAMS IN PORTFOLIO.  Full Article

Concert Pharmaceuticals Reports Year Ended 2018 Financial Results
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS YEAR ENDED 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON CLINICAL PROGRAMS.CONCERT PHARMACEUTICALS INC - CTP-692 POISED TO ADVANCE INTO PHASE 2 DEVELOPMENT BY YEAR END 2019 AS ADJUNCTIVE TREATMENT FOR SCHIZOPHRENIA.CONCERT PHARMACEUTICALS INC - REVENUE WAS $10.5 MILLION FOR YEAR ENDED DECEMBER 31, 2018, COMPARED TO $143.9 MILLION FOR YEAR ENDED DECEMBER 31, 2017.  Full Article

Concert Pharmaceuticals Reports Positive Results For CTP-543
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS REPORTS POSITIVE CTP-543 RESULTS FROM INTERIM ANALYSIS OF PHASE 2A TRIAL IN PATIENTS WITH ALOPECIA AREATA.CONCERT PHARMACEUTICALS INC - CTP-543 ACHIEVED ITS PRIMARY ENDPOINT IN 8 MG TWICE-DAILY COHORT.CONCERT PHARMACEUTICALS INC - NO SERIOUS ADVERSE EVENTS WERE REPORTED.CONCERT PHARMACEUTICALS - RESULTS FROM COMPLETE CTP-543 PHASE 2A TRIAL, INCLUDING 12 MG COHORT, EXPECTED IN Q3 2019.  Full Article

Concert Pharmaceuticals Amends Protocol Of Phase 2A Trial To Evaluate 12 Mg Twice-Daily Dose Cohort Of Ctp-543 For Treatment Of Alopecia Areata
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Concert Pharmaceuticals Inc ::CONCERT PHARMACEUTICALS AMENDS PROTOCOL OF PHASE 2A TRIAL TO EVALUATE 12 MG TWICE-DAILY DOSE COHORT OF CTP-543 FOR THE TREATMENT OF ALOPECIA AREATA.CONCERT PHARMACEUTICALS INC - COMPANY ON TRACK TO REPORT TOPLINE DATA FROM 4 MG AND 8 MG TWICE-DAILY COHORTS IN Q4 OF 2018.CONCERT PHARMACEUTICALS INC - PROTOCOL AMENDMENT PROVIDES FOR ADDITIONAL PATIENTS TO BE ENROLLED IN TRIAL.  Full Article

BRIEF-Concert Pharmaceuticals Selected For Late-Breaking Oral Presentation Of CTP-543 Phase 2 Data In Alopecia Areata

* CONCERT PHARMACEUTICALS SELECTED FOR LATE-BREAKING ORAL PRESENTATION OF CTP-543 PHASE 2 DATA IN ALOPECIA AREATA AT THE 2020 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING Source text for Eikon: Further company coverage: